Investors & Media

Stay up to date with media information, recent press releases and investor information from Genprex.

Investors


Please visit again soon. This section is under construction and will be ready shortly. We appreciate your patience.

In the mean time...

View Our Press Releases

Media


Genprex Files Registration Statement For Proposed Initial Public Offering


Genprex, Inc., a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Genprex intends to apply to list its common stock on the NASDAQ Capital Market, under the ticker symbol “GNPX.”

Full Press Release

Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer


Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice. The research was presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C.

Full Press Release

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex ™ for Late Stage Non-Small Cell Lung Cancer


Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients.

Full Press Release

Genprex Retains ICR Healthcare as Integrated Strategic Communications Counsel


Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that it has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program. The program will combine investor relations, public relations and digital communications to advance the objective of raising the profile of Genprex and its lead candidate Oncoprex, which is currently in a Phase II trial for the treatment of non-small cell lung cancer (NSCLC).

Full Press Release

Genprex Expands Executive Management Team and Completes Funding


Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer. Dr. Pham joins Genprex after previously serving as Founder and Chief Medical Officer at RubiconMD and as a clinical faculty member at Harvard Medical School. Dr. Pham brings with him nearly 20 years of experience at the forefront of innovation in academic medicine and healthcare entrepreneurship. “Dr. Pham’s leadership and scientific expertise are excellent assets for Genprex. The addition of Dr. Pham to our team demonstrates our desire to import technical talent to the state of Texas,” stated Rodney Varner, CEO of Genprex.

Full Press Release

Genprex Signs Capital Markets Advisory Agreement with Network 1 Financial as Part of an Overall Financing Plan


Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate. Upon completion of the initial phase of this agreement, which is expected to occur well before the end of this year, the Company intends to put in place an overall plan with Network 1 Financial to provide for its immediate and long term capital needs and for the ultimate goal of being a public company.

Full Press Release

Leading Surgeon, Researcher Jack A. Roth, MD, Named 2015 ASTRO Honorary Member


Genprex, Inc. announced today that Jack A. Roth, MD FACS, Chairman of the Genprex Scientific and Medical Advisory Board, has been selected as the 2015 Honorary Member of The American Society for Radiation Oncology (ASTRO). Dr. Roth, recognized as a leading surgeon and distinguished cancer researcher, received the highest honor ASTRO bestowed to scientists and leaders in disciplines other than radiation oncology, radiobiology, or radiation physics. The induction as the 2015 ASTRO Honorary Member will be held at ASTRO’s 57th Annual Meeting at the Henry B. Gonzalez Center in San Antonio, Texas.

Genprex, Inc. announced today that Jack A. Roth, MD FACS, Chairman of the Genprex Scientific and Medical Advisory Board, has been selected as the 2015 Honorary Member of The American Society for Radiation Oncology (ASTRO). Dr. Roth, recognized as a leading surgeon and distinguished cancer researcher, received the highest honor ASTRO bestowed to scientists and leaders in disciplines other than radiation oncology, radiobiology, or radiation physics. The induction as the 2015 ASTRO Honorary Member will be held at ASTRO’s 57th Annual Meeting at the Henry B. Gonzalez Center in San Antonio, Texas.

Full Press Release

Genprex Begins Phase II Clinical Trial for Lung Cancer


Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.

Full Press Release

Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients


A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. The clinical trial results were published April 26, 2012 in a paper entitled, “Phase I Clinical Trial of Systemically Administered TUSC2 (FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans” in the journal PLoS One, an international, peer-reviewed publication of the Public Library of Science. The publication is available here.

Full Press Release

SPORE Grants Turn Into Hope for Patients (the story of Maria Escalera)


The team behind the treatment of Maria Escalara with DOTAP:Chol(TUSC2)

“Imagine a cancer treatment so promising someone travels 5,000 miles to MD Anderson to receive it.

That person is Maria Escalera.

That treatment is an experimental gene therapy drug called FUS1 nanoparticle. Escalera got to MD Anderson from her home in Venezuela by airplane. The drug got to the clinic by way of a unique type of funding called a Specialized Programs of Research Excellence, or SPORE, grant.”

Link here.